Rectalcancer rectalcarcinoma
Conditions
Interventions
None listed
Sponsors
Heelkunde
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with rectal cancer who are eligible for treatment with neoadjuvant chemoradiation Patients treated in the LUMC, HMC, Alrijne or GHZ. Age 18 years and older; Willing to participate in all aspects of the study
Exclusion criteria
Exclusion criteria: Patients with rectal cancer, receiving chemoradiation as part of the TESAR trial Diabetes mellitus Claustrofobia (low dose benzodiazepines are allowed); Prior radiotherapy to the pelvis If female and fertile: signs and symptoms of pregnancy or a positive pregnancy test / breast-feeding (a formal negative pregnancy test is not obligatory); Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule Contraindications for Magnetic Resonance Imaging Patient has evidence of infection in the 14 days prior to the FDG-PET/CT scan localised to the lower abdomen, pelvic region, lower back, inguinal region; Inability to tolerate lying supine for the duration of an FDG-PET/CT examination (~30min)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the accuracy of the combination of clinical data, MRI and digital FDG-PET/CT for prediction of response to chemoradiation therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| NVT | — |
Countries
Netherlands
Outcome results
None listed